Drugs / PM8001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05537051 | Oct 2023 → Oct 2024 | cancer | BioNTech SE | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PM8001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05537051 ↗ |
| Action | Inhibit | “PM8001 (Anti-PD-L1/TGF-β)” NCT05537051 ↗ |
| Modality | Protein / enzyme biologic | “PM8001 (a PD-L1/TGF-beta bispecific Fc fusion protein)” NCT05537051 ↗ |